血清VEGF-C、VEGFR-2、3表达水平在急性白血病疗效监测及预后判断中的应用

Application of Serum VEGF-C,VEGFR-2 and VEGFR-3 Expression Level in Monitoring Curative Effects and Prognosis of Acute Leukemia

目的观察AL患者血清中VEGF-C及VEGFR-2、VEGFR-3表达水平,探讨其临床意义.方法采用酶联免疫吸附法对51例确诊为AL患者、接受治疗观察的43例及16例健康献血者血清中VEGF-C、VEGFR-2、3进行检测.结果 (1)AL患者VEGF-C、VEGFR-2及VEGFR-3水平,较正常对照组高,差异有统计学意义(P<0.01);(2)治疗后完全缓解(CR)组患者VEGF-C和VEGFR-2水平较治疗前降低,差异有统计学意义(P<0.01);治疗后未完全缓解(NR)组患者VEGF-C和VEGFR-2水平较治疗前降低,但差异无统计学意义(P>0.05);(3)治疗后CR组和NR组VEGFR-3水平较治疗前无明显变化(P>0.05);(4)治疗前NR组VEGFR-2、VEGFR-3水平明显高于CR组,具有统计学意义(P<0.01).结论观察AL患者治疗前后VEGF-C及VEGFR-2、3表达水平,对预后判断、疗效评估和病情监测具有重要临床意义.

Objective To observe expression level of serum vascular endothelial growth factor-C （ VEGF-C） , VEGF-C receptor-2 and VEGF-C receptor-3 in patients with acute leukemia （AL） and to explore its clinical significance. Methods Enzyme-linked immuno sorbent assay （ELISA） was used to detect the serum expression levels of VEGF-C, VEGFR-2, and VEGFR-3 of 51 patients diagnosed with acute leukemia, 43 patients under medical treatment and 16 healthy blood donors. Results （1） Serum VEGF-C, VEGFR-2, and VEGFR-3 expression levels in AL patients were significantly higher than those in normal control group. （2） Serum VEGF-C and VEGFR-2 expression levels in complete remission （CR） group significantly declined after treatment. Serum VEGF-C and VEGFR-2 expression levels in non-complete remission （NR） group slightly declined after treatment but no significant difference was found （P〉0.05） （3） No significant difference was found in serum VEGFR-3 expression levels both in CR group and NR group after treatment （P〉O.05） （4） Serum VEGF-C, VEGFR-2, and VEGFR-3 expression levels in NR group were significantly higher than those in CR group before treatment （P〈O.08） . Conclusions Observing serum expression level of VEGF-C, VEGFR-2, and VEGFR-3 ofAL patients may be helpful in monitoring curative effects and prognosis of acute leukemia.